Please login to the form below

Not currently logged in
Email:
Password:

RIPK1 inhibitor

This page shows the latest RIPK1 inhibitor news and features for those working in and with pharma, biotech and healthcare.

Lilly signs $960m deal with Rigel to develop RIPK1 inhibitors

Lilly signs $960m deal with Rigel to develop RIPK1 inhibitors

Rigel already has ongoing pre-clinical activities with its lead CNS penetrant RIPK1 inhibitor candidates. ... The ethos behind RIPK1 inhibitor development is to offer a new kind of approach towards treating a range of autoimmune, inflammatory and

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Medscape Education Global

Medscape delivers dynamic, innovative education to optimize learner engagement and patient outcomes worldwide....

Latest intelligence

Early communications in Pharma: How effective pre-approval comms delivers launch success
What communications are required for a successful launch...
Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...